Egwuregwu na itinye ha n'ọrụ na ihe mgbaru ọsọ na ndụ, ihe a na-akpọ "mixing," na-aga n'ihu na ọsọ ọsọ na-ekele ụwa ụwa anyị. Egwuregwu dị iche iche emeela ọtụtụ ebe dị iche iche, gụnyere egwuregwu ndị na-emeziwanye onwe ha, egwuregwu iji gbaa ndụ mgbanwe dị mma, na ọbụna egwuregwu iji mee ka mkpali na-akpali iji mezuo ebumnuche ọrụ.
Genentech, otu ụlọ ọrụ na-ahụ maka ọrịa biopharmaceutical, na-agbakọta usoro sayensị na-agwọ ọrịa-ọ bụghị nanị ha. Ma, olee otú nkwurịta okwu si emetụta ndị ọrịa cancer? Ọfọn, maka onye nwere ọrịa kansa, ịnwa ịhazi maka ọdịnihu nwere ike ịba ụba. Ndị ọkà mmụta sayensị, okwu nchịkwa, mmebi okwu, na ngọngọ anaghị enyere aka. Dịka ọmụmaatụ, dịka ọmụmaatụ, enwere ike tụọ n 'ụzọ dịgasị iche iche, nke a nwekwara ike ịgwọ ọrịa ọrịa cancer kansa. Nke ahụ bụ ebe Mission: MRD dabara na.
Mission: MRD
Genentech ekepụtara egwuregwu ọhụrụ nke isii nke isii, Mission: MRD, iji kụziere ndị mmadụ banyere ọrịa ole na ole (MRD) - otu ụzọ isi atụghachi omume onye ọrịa cancer ma ọ bụ usoro.
Ọtụtụ ụdị ọrịa cancer ọbara- gụnyere agụ ọrịa leukemia na-adịghị ala ala (CLL), ọrịa leukemia kachasị na-arịakarị - bụ ụdị dị mkpa ka a na-achịkwa ọgwụgwọ ọrịa cancer n'oge na-adịghị anya, nke pụtara na ị gaghị ekpochapụ cell cancer ọ bụla.
Nke a na - eduga na nlọghachite, ya mere ndi dọkịta na - agbalị ịkpachara anya mgbe ọ bịara n'okwu ahụ bụ "ọgwụgwọ."
Na Mission: MRD, onye ọrụ na-agafe n'ọbara, na-ebibi ọtụtụ mkpụrụ ndụ cancer ka ha nwere ike iji ihe mgbaru ọsọ nke iru MRD-negativity. Ọ dị mkpa iburu n'uche na egwuregwu a bụ isi maka ntụrụndụ ma ọ bụghị na-eche na ị ga-ahụ maka ahụike ma ọ bụ nke sayensị, kama ọ bụ ịmata maka ọnọdụ MRD.
MRD-Negativity
Mgbe onye nwere CLL rute na MRD-negativity, ọ pụtara na ọ dịghị mkpụrụ ndụ cancer nwere ike ịchọta ọbara ma ọ bụ ụbụrụ ọkpụkpụ ọkpụkpụ site na iji nyocha ụfọdụ. Ugbu a, maka cancer dị ka CLL, ọ ka nwere ike ịmalite ọrịa, ọbụna mgbe onye ọrịa rutela MRD-negativity; Otú ọ dị, iru MRD-negativity dị nnọọ ka ọ bụ ezigbo ihe na ebe a bụ ihe mere:
- Enwere ọtụtụ ụzọ iji tụọ ọrịa ọrịa na ọrịa cancer. Ọnọdụ MRD na-ezighị ezi na CLL ka enwere ike iji teknụzụ kachasị ọhụrụ, nke siri ike.
- Mgbe onye nwere CLL rute MRD-negativity, ọ pụtara na ọ dịghị ọrịa cancer nwere ike ịchọta ọbara ma ọ bụ ụbụrụ ọkpụkpụ ọkpụkpụ site na iji nyocha kpọmkwem nke na-eji ụzọ ndị ọzọ kariri ụzọ ochie nke ịgụ mkpụrụ ndụ kwa 100 n'okpuru microscope.
- MRD-negativity nwere ike jikọtara na mma. A ghaghị ịrụ ọrụ ọzọ mana otu ihe àmà na-arịwanye elu na-egosi na MRD-negativity mgbe ụfọdụ ọgwụgwọ nwere ike ịkọ ogologo remission na ikekwe ogologo oge lanarị maka ọtụtụ ọrịa cancer ọbara.
Egwuregwu Ọrịa Cancer
A na-ezube egwuregwu ndị ọzọ na ihe dịgasị iche iche na foto dị iche iche dị na ebe nrụọrụ Genentech iji nyere gị aka ịghọta usoro mgbagwoju anya nke cancer - usoro nke na-eduga ná mmepe nke nchebe na-egbochi ọrịa cancer.
Isi mmalite:
Smolej L, Mmasị M. Ụzọ dị mma maka njikwa nke ọrịa leukemia lymphocytic na-adịghị ala ala. Akụkọ nke Medical Science: AMS. 2016; 12 (2): 448-456.
Hallek M, Cheson BD, Catovsky D, et al. Ntuziaka maka nyocha na ọgwụgwọ ọrịa leukemia na-adịghị ala ala: otu akụkọ sitere na International Workshop on Chronic Lymphocytic Leukemia na-emelite usoro ntụziaka nke National Cancer Institute-Working Group 1996. Ọbara . 2008; 111: 5446-56.
Hallek M, Fischer K, Fingerle-Rowson G, et al. Mgbakwunye nke rituximab na fludarabine na cyclophosphamide na ndị ọrịa na-arịa ọrịa leukemia lymphocytic na-adịghị ala ala: otu nke a na-emeghe, na-emeghe aha, usoro nke 3. Lancet. 2010; 376: 1164-74.
Bottcher S, Ritgen M, Fischer K, et al. Ngwuputa ihe omimi nke ihe omuma bu onye nwere onwe ya bu onye nwere onwe ya na onu ogugu ogwu na-egbuke egbuke: otutu nyocha site na GCLLSG CLL8 ikpe. J Clin Oncol . 2012; 30: 980-8.